𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson's disease and concurrent depression

✍ Scribed by Paulo S. Boggio; Felipe Fregni; Felix Bermpohl; Carlos G. Mansur; Moacyr Rosa; Demetrio O. Rumi; Egberto R. Barbosa; Marina Odebrecht Rosa; Alvaro Pascual-Leone; Sérgio Paulo Rigonatti; Marco A. Marcolin; Maria Teresa Araujo Silva

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
113 KB
Volume
20
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Previous studies show that cognitive functions are more impaired in patients with Parkinson's disease (PD) and depression than in nondepressed PD patients. We compared the cognitive effects of two types of antidepressant treatments in PD patients: fluoxetine (20 mg/day) versus repetitive transcranial magnetic stimulation (rTMS, 15 Hz, 110% above motor threshold, 10 daily sessions) of the left dorsolateral prefrontal cortex. Twenty‐five patients with PD and depression were randomly assigned either to Group 1 (active rTMS and placebo medication) or to Group 2 (sham rTMS and fluoxetine). A neuropsychological battery was assessed by a rater blind to treatment arm at baseline and 2 and 8 weeks after treatment. Patients in both groups had a significant improvement of Stroop (colored words and interference card) and Hooper and Wisconsin (perseverative errors) test performances after both treatments. Furthermore, there were no adverse effects after either rTMS or fluoxetine in any neuropsychological test of the cognitive test battery. The results show that rTMS could improve some aspects of cognition in PD patients similar to that of fluoxetine. The mechanisms for this cognitive improvement are unclear, but it is in the context of mood improvement. © 2005 Movement Disorder Society

📜 SIMILAR VOLUMES

The effects of fluoxetine and dothiepin
The effects of fluoxetine and dothiepin on cognitive function in depressed patients in general practice
✍ D. B. Fairweather; N. Stanley; J. S. Yoon; I. Hindmarch 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB 👁 2 views

The objective of this study was to assess whether there are any dierences between ¯uoxetine and dothiepin on cognitive function of patients with major depression (DSMIII-R). A randomized, double-blind, parallel group design, 6 week trial in patients in general practice was employed where patients we

A double blind comparison of the effects
A double blind comparison of the effects of fluoxetine and amitriptyline on cognitive function in elderly depressed patients
✍ D. B. Fairweather; J. S. Kerr; D. A. Harrison; C. A. Moon; I. Hindmarch 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 444 KB 👁 2 views

Sixty-six elderly depressed patients received fluoxetine 20 mg (FLU) or amitriptyline 75 mg (AMI) for 42 days in a double blind parallel group study. Each week, subjects completed a test battery which is sensitive to the residual effects of psychoactive drugs. The results show that FLU and AM1 were

Effects of levodopa and subthalamic nucl
Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson's disease
✍ Aurélie Funkiewiez; Claire Ardouin; Roshan Cools; Paul Krack; Valérie Fraix; Ali 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB 👁 1 views

## Abstract In Parkinson's disease (PD), levodopa and subthalamic nucleus (STN) stimulation lead to major improvement in motor symptoms. Effects of both treatments on cognition and affective status are less well understood. Motor, cognitive, and affective symptoms may relate to the dysfunctioning o

Effect of rivastigmine on tremor in pati
Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia
✍ Tanya Y. Gurevich; Herzel Shabtai; Amos D. Korczyn; Ely S. Simon; Nir Giladi 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 1 views

## Abstract The purpose of this study was to assess whether rivastigmine, a cholinergic agent, affects tremor features when given to improve cognition in demented Parkinson's disease (PD) patients. Demented PD patients (n = 26; Mini‐Mental State Examination score, 13–25; age, 75.2 ± 4.9 yr) were gi